Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges

Penumbra Inc

2024-Q2 EPS reported -$1.27 revenue$578,058,000

U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).
GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.
Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).
Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.
Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.